Immunotherapy News and Research

Latest Immunotherapy News and Research

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.

26 Nov 2014

Eminent molecular cell biologist awarded GRC fellowship

The Gutenberg Research College of Johannes Gutenberg University Mainz has awarded the coveted GRC fellowship to Professor Krishnaraj Rajalingam. In the upcoming years, he will lead a research team at the Research Center for Immunotherapy at Mainz University.

26 Nov 2014

LaVision BioTec report on Dr Friedl’s research and his imaging of cancer growth

LaVision BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Peter Friedl and his imaging of cancer growth using intravital microscopy.

25 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

24 Nov 2014

Researchers discover why only some patients respond to ipilimumab drug

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not. MSK was at the forefront of the clinical research that brought this CTLA-4 blocking antibody to melanoma patients.

23 Nov 2014

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity.

21 Nov 2014

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade.

21 Nov 2014

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.

20 Nov 2014

Moffitt announces development of innovative investigational biologic agent for MDS

In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.

18 Nov 2014

Edison announces initiation of full coverage on ADRs of DBV Technologies

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage on the US-listed ADRs of DBV Technologies, the French allergy company focused on peanut allergy.

18 Nov 2014

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

18 Nov 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Beckman Coulter Life Sciences participates in the ONE Study, international collaboration of scientists across Europe and the USA.

From Beckman Coulter Life Sciences - Flow Cytometry 17 Nov 2014

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).

14 Nov 2014

Unique immunochemotherapy approach to treating pancreatic cancer

VCU Massey Cancer Center and VCU Institute of Molecular Medicine researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy - a combination of chemotherapy and immunotherapy, which uses the patient's own immune system to help fight against disease.

13 Nov 2014

RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

Cancer researchers at Roswell Park Cancer Institute have identified two independent classes of novel candidate prognostic markers for ovarian cancer, advancing efforts to develop targeted therapies for the disease. The findings resulted from two separate studies published in the peer-reviewed journal PLoS ONE and based on data from The Cancer Genome Atlas (TCGA), the world's largest public database on gene expression in different tumor types.

12 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

New research brings personalized cancer vaccine approach one step closer to reality

Scientists make breakthrough in developing new treatment for advanced bladder cancer

CARsgen announces completion of series A financing

Eminent molecular cell biologist awarded GRC fellowship

LaVision BioTec report on Dr Friedl’s research and his imaging of cancer growth

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Researchers discover why only some patients respond to ipilimumab drug

Protein complex plays key role in detecting tumor cells, promotes anti-tumor response

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Moffitt announces development of innovative investigational biologic agent for MDS

Edison announces initiation of full coverage on ADRs of DBV Technologies

TapImmune signs new collaborative research agreement with VGTI Florida

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Study gives a roadmap for future brain cancer vaccines

Unique immunochemotherapy approach to treating pancreatic cancer

RPCI researchers identify two novel candidate prognostic markers for ovarian cancer

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Immunotherapy News and Research

Latest Immunotherapy News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in